On 29th November 2022, NJ Bio, Inc., had the distinct pleasure of welcoming a good friend and mentor, Dr. Thomas (Tom) Nittoli from Regeneron Pharmaceuticals, Inc. to share his views on advancing conjugated antibodies and proteins from discovery to development of next-generation antibody drug conjugates (ADCs). Tom is currently Senior Director at Regeneron Pharmaceuticals. He is a dynamic pharmaceutical executive with more than 20 years of expertise in drug discovery. He has been the lead inventor on several key patent filings and is a renowned scientific leader in developing candidates for the treatment of cancer and infectious diseases.
Tom presented on a novel conjugation technology which is soon to be published. The focus of the talk was on advanced chemical and biotechnological strategies for the site-directed conjugation of drugs in next-generation ADCs. He also elaborated on how site-specific methods offer advantages in enhancing the conjugate’s properties and functions.
Later, Tom inaugurated the new cGMP Quality Control laboratory at NJ Bio, headquarters in Princeton. This new capability will help NJ Bio, meet the ever-growing demand for GMP-compliant analytical services for ADCs and small molecules. The CRO is now a step closer to its vision of providing additional value-added services to accelerate clients’ development programs. This was indeed a very rewarding experience for the entire NJ Bio team!
